Skip to main content
Premium Trial:

Request an Annual Quote

GSK Licenses NMR Processing Software from ACD/Labs

NEW YORK, June 13 (GenomeWeb News) - Advanced Chemistry Development (ACD/Labs) said last week that GlaxoSmithKline will deploy its NMR Prediction and Processing software modules across its worldwide discovery research centers.

Under the agreement, scientists at GSK research centers in Europe and the US will use ACD/Labs NMR Processors for processing and analysis, as well as the ACD/CNMR Predictor for calculating chemical shifts and coupling constants for 13C NMR spectra. ACD/2D NMR Manager will also be installed at various locations to provide specialists with 2D NMR verification capabilities, the company said.

ACD/Combi NMR will also be installed at GSK's Stevenage, UK, and Research Triangle Park, NC, sites.

Financial terms for the licensing agreement were not disclosed.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.